Axonics, Inc. (AXNX)
NASDAQ: AXNX · IEX Real-Time Price · USD
-0.11 (-0.16%)
May 24, 2024, 4:00 PM EDT - Market closed

Company Description

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction.

Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.

The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence.

It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally.

The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021.

Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Axonics, Inc.
Axonics logo
Country United States
Industry Medical Devices
Sector Healthcare
Employees 797
CEO Raymond W. Cohen

Contact Details

26 Technology Drive
Irvine, California 92618
United States
Phone 949-396-6322

Stock Details

Ticker Symbol AXNX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001603756
CUSIP Number 05465P101
ISIN Number US05465P1012
Employer ID 45-4744083
SIC Code 3841

Key Executives

Name Position
Raymond W. Cohen Chief Executive Officer and Director
Rinda K. Sama Chief Operating Officer
Dr. John Woock Ph.D. Executive Vice President, Chief Marketing and Strategy Officer
Alfred J. Ford Jr. Chief Commercial Officer
Kari Keese Chief Financial Officer
Guangqiang Jiang Ph.D. Chief Technology Officer
Neil Bhalodkar Vice President of Investor Relations
Aaron Pettit General Counsel and Chief Compliance Officer
Michael V. Williamson Esq., J.D. Senior Vice President, General and IP Counsel
Dr. Karen L. Noblett M.A.S., M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Apr 30, 2024 10-Q Quarterly Report
Apr 30, 2024 8-K Current Report
Apr 29, 2024 10-K/A [Amend] Annual report
Apr 4, 2024 8-K Current Report
Mar 25, 2024 8-K Current Report
Mar 7, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Feb 29, 2024 10-K Annual Report
Feb 28, 2024 8-K Current Report
Feb 22, 2024 DEFM14A Filing
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals